![Pascal Krotee](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Pascal Krotee
Private Equity Investor bei
RiverVest Venture Management LLC
Profil
Pascal Krotee currently works at RiverVest Venture Management LLC, as Principal from 2023.
Dr. Krotee also formerly worked at Holoclara, Inc., as Board of Directors from 2019 to 2021, Kairos Venture Investments LLC, as Investment Associate from 2017 to 2021, and Linnaeus Therapeutics, Inc., as Linnaeus Therapeutics from 2019 to 2021.
Dr. Krotee received her doctorate degree from the University of California, Los Angeles and undergraduate degree from the University of California, Irvine.
Aktive Positionen von Pascal Krotee
| Unternehmen | Position | Beginn |
|---|---|---|
RiverVest Venture Management LLC
 RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Partners invests in companies located in the United States. The firm focuses on life sciences, primarily on medical devices and biopharma sectors. It provides financing for early-stage capital requirements. It act as a lead investor. | Private Equity Investor | 01.12.2023 |
Ehemalige bekannte Positionen von Pascal Krotee
| Unternehmen | Position | Ende |
|---|---|---|
Kairos Venture Investments LLC
 Kairos Venture Investments LLC Investment ManagersFinance Kairos Ventures invests in companies located in the United States. The firm focuses on life sciences, physical sciences, and technology sector. It provides financing for early-stage capital requirements with an investment size of USD 0.15 - USD 20 million. | Private Equity Investor | 28.02.2021 |
Holoclara, Inc.
 Holoclara, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapy drugs to autoimmune disorders | Direktor/Vorstandsmitglied | 28.02.2021 |
Linnaeus Therapeutics, Inc.
 Linnaeus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for cancer | Direktor/Vorstandsmitglied | 28.02.2021 |
Ausbildung von Pascal Krotee
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
7
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Partners invests in companies located in the United States. The firm focuses on life sciences, primarily on medical devices and biopharma sectors. It provides financing for early-stage capital requirements. It act as a lead investor. | Finance |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kairos Venture Investments LLC
Kairos Venture Investments LLC Investment ManagersFinance Kairos Ventures invests in companies located in the United States. The firm focuses on life sciences, physical sciences, and technology sector. It provides financing for early-stage capital requirements with an investment size of USD 0.15 - USD 20 million. | Finance |
Linnaeus Therapeutics, Inc.
Linnaeus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for cancer | Health Technology |
Holoclara, Inc.
Holoclara, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapy drugs to autoimmune disorders | Health Technology |
